



## **Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference**

February 27, 2014

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 26, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 34<sup>th</sup> Annual Cowen and Company Health Care Conference at 10:00 a.m. EST/7:00 a.m. PST on Tuesday, March 4, 2014 in Boston.

During the presentation, Dr. Morrissey will review the company's development plans and priorities for cabozantinib in 2014. He will also discuss the company's corporate strategy and financial outlook, and provide a general business update.

The presentation will be webcast and may be accessed via the Event Calendar page under Investors & Media at [www.exelixis.com](http://www.exelixis.com).

### **About Exelixis**

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ® (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.  
Charles Butler, 650-837-7277  
Vice President  
Investor Relations and Corporate Communications  
[cbutler@exelixis.com](mailto:cbutler@exelixis.com)